Jingming Wang, PhD, joined the Office of Technology Development as an Immunotherapy Project Manager in January 2024. She manages product development, commercialization, business growth, and licensing for select MSK immunotherapy assets.

Previously, Jingming worked as a Client Relationship Manager at the CRO Business Development Unit at Genesis Biotechnology Group. She also served as a Senior Platform Biologist/Project Manager at Roivant Sciences, where she managed various ML/AI drug discovery projects in partnership with large pharmaceutical companies.

Jingming received her PhD degree in Pharmacology from Stony Brook University in 2018 and then conducted immunotherapy drug discovery research at Dr. Timothy Chan’s lab at MSKCC from 2019 to 2021.